Advanced Heart Failure: Recognising When to Refer

Most people with heart failure are managed well with medicines and devices. A minority — roughly one in twenty patients with heart failure each year — progress to advanced, or stage D, disease, in which symptoms persist at rest or on minimal exertion despite optimal treatment. At that point, advanced therapies — mechanical circulatory support or transplantation — become the relevant options, and outcomes depend heavily on whether the patient reaches a centre that can offer them before irreversible deterioration. The 2021 AHA scientific statement addresses a specific gap: delayed or absent referral.

Recognising advanced heart failure

The clinical markers are cumulative rather than single: breathlessness or fatigue at rest or with minimal activity; repeated hospital admissions for congestion or low output; inability to tolerate guideline-directed medicines because blood pressure or kidney function will not allow it; progressive worsening of kidney or liver function; persistently high natriuretic peptide levels; worsening right-heart function or valve regurgitation; and repeated defibrillator shocks. Patients who seem "fine" between admissions but require escalating diuretics, or who are losing weight and muscle, are also in this group. The statement treats these as triggers for referral discussion, not as criteria to be met in full.

Why timing matters

Patients referred early have better survival with advanced therapies and better outcomes after transplantation, because the window closes: prolonged congestion damages the kidneys and liver, cachexia and frailty reduce surgical tolerance, pulmonary hypertension may become fixed and irreversible, and social and financial circumstances become harder to arrange under time pressure. Conversely, referral is not a commitment to transplantation — assessment may conclude that optimised medical therapy, a ventricular assist device as destination therapy, or specialist palliative care is the better path. The value of the referral is the expertise applied to the decision.

What assessment involves

A specialist centre evaluates the heart itself — function, valves, rhythm, congenital anatomy — and whether reversible contributors remain: untreated coronary disease, uncontrolled thyroid disease, alcohol, sleep apnoea, or non-adherence. Exercise capacity (usually a six-minute walk or cardiopulmonary exercise testing), kidney and liver function, invasive haemodynamic assessment in selected cases, and a review of frailty and nutrition complete the picture. Equally important is assessment of the non-medical dimensions: social support, ability to attend follow-up, and financial access to lifelong medication and monitoring.

The treatment options discussed

These range from intensification and redesign of medical therapy, through device therapy (cardiac resynchronisation, defibrillators), to durable mechanical support — a left ventricular assist device, either as a bridge to transplantation or as destination therapy for those who are not transplant candidates — and heart transplantation. Each carries specific eligibility considerations: age, other organ disease, cancer history, infection, pulmonary pressures, adherence and support network.

What patients and families can do

Ask the question directly: "could this be advanced heart failure, and should I be seen at a centre that does transplants and assist devices?" Keep a written record of admissions, medicines tried and stopped, and why. Discuss preferences early, including what level of intervention you would want. And recognise that specialist palliative care alongside active heart failure treatment improves symptom control and quality of life — it is not a signal that treatment has stopped.